CL2011002610A1 - Metodo de terapia complementaria que comprende la administracion a un paciente con cancer luego de la cirugia definitiva de un antagonista especifico del factor de crecimiento endotelial vascular (vegf) durante mas de un ano; y kit. - Google Patents
Metodo de terapia complementaria que comprende la administracion a un paciente con cancer luego de la cirugia definitiva de un antagonista especifico del factor de crecimiento endotelial vascular (vegf) durante mas de un ano; y kit.Info
- Publication number
- CL2011002610A1 CL2011002610A1 CL2011002610A CL2011002610A CL2011002610A1 CL 2011002610 A1 CL2011002610 A1 CL 2011002610A1 CL 2011002610 A CL2011002610 A CL 2011002610A CL 2011002610 A CL2011002610 A CL 2011002610A CL 2011002610 A1 CL2011002610 A1 CL 2011002610A1
- Authority
- CL
- Chile
- Prior art keywords
- vegf
- year
- kit
- administration
- growth factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fertilizers (AREA)
Abstract
Método de terapia complementaria que comprende la administración a un paciente con cáncer luego de la cirugía definitiva de un antagonista específico del factor de crecimiento endotelial vascular (vegf) durante más de un año; y kit.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17100809P | 2009-04-20 | 2009-04-20 | |
US17131809P | 2009-04-21 | 2009-04-21 | |
US18119509P | 2009-05-26 | 2009-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011002610A1 true CL2011002610A1 (es) | 2012-04-09 |
Family
ID=42235124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011002610A CL2011002610A1 (es) | 2009-04-20 | 2011-10-19 | Metodo de terapia complementaria que comprende la administracion a un paciente con cancer luego de la cirugia definitiva de un antagonista especifico del factor de crecimiento endotelial vascular (vegf) durante mas de un ano; y kit. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20100266589A1 (es) |
EP (1) | EP2421558A1 (es) |
JP (1) | JP2012524083A (es) |
KR (1) | KR20120096401A (es) |
CN (1) | CN102458467A (es) |
AR (1) | AR076344A1 (es) |
AU (1) | AU2010239368A1 (es) |
BR (1) | BRPI1006438A2 (es) |
CA (1) | CA2759030A1 (es) |
CL (1) | CL2011002610A1 (es) |
CO (1) | CO6450651A2 (es) |
CR (1) | CR20110553A (es) |
IL (1) | IL215764A0 (es) |
MA (1) | MA33323B1 (es) |
MX (1) | MX2011010955A (es) |
RU (1) | RU2011147051A (es) |
SG (1) | SG175289A1 (es) |
TW (1) | TW201106969A (es) |
WO (1) | WO2010123891A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA018260B1 (ru) * | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
CN102821600B (zh) | 2009-12-25 | 2016-01-20 | 中外制药株式会社 | 使用移植了nog确立癌细胞株的非人动物模型进行的抗癌药靶探索以及筛选方法 |
MY191929A (en) | 2010-06-03 | 2022-07-18 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
EP2626414B1 (en) | 2010-10-06 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell mass and process for production thereof |
US10018630B2 (en) | 2011-09-07 | 2018-07-10 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
US20140302511A1 (en) * | 2011-10-28 | 2014-10-09 | Pharmalogicals Research Pte. Ltd. | Cancer stem cell-specific molecule |
CA2874144C (en) * | 2012-05-31 | 2023-12-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
WO2014025813A1 (en) * | 2012-08-07 | 2014-02-13 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
EP2914961A4 (en) | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4 |
PE20151604A1 (es) | 2012-11-02 | 2015-11-04 | Pharmacyclics Llc | Terapia adyuvante con inhibidores de quinasa de la familia tec |
WO2014190311A2 (en) * | 2013-05-24 | 2014-11-27 | Nsabp Foundation, Inc. | Defective mismatch repair and benefit from bevacizumab for colon cancer |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2017042318A1 (en) * | 2015-09-10 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chemerin polypeptide for the treatment of cancer-induced cachexia |
CN109071644B (zh) | 2015-09-23 | 2023-09-19 | 昂考梅德药品有限公司 | 治疗癌症的方法和组合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5730977A (en) * | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
PT1325932E (pt) * | 1997-04-07 | 2005-06-30 | Genentech Inc | Anticorpos anti-vegf |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
KR20180014881A (ko) * | 2003-05-30 | 2018-02-09 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US7758859B2 (en) * | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
US20060009360A1 (en) * | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
JP2010513566A (ja) * | 2006-12-19 | 2010-04-30 | ジェネンテック, インコーポレイテッド | アジュバント療法およびネオアジュバント療法のためのvegf特異的アンタゴニストと初期ステージ腫瘍の治療 |
EP2125016A2 (en) * | 2007-02-01 | 2009-12-02 | Genetech, Inc. | Combination therapy with angiogenesis inhibitors |
TWI580694B (zh) * | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
-
2010
- 2010-04-20 WO PCT/US2010/031740 patent/WO2010123891A1/en active Application Filing
- 2010-04-20 BR BRPI1006438A patent/BRPI1006438A2/pt not_active IP Right Cessation
- 2010-04-20 MX MX2011010955A patent/MX2011010955A/es not_active Application Discontinuation
- 2010-04-20 US US12/763,704 patent/US20100266589A1/en not_active Abandoned
- 2010-04-20 MA MA34342A patent/MA33323B1/fr unknown
- 2010-04-20 AR ARP100101306A patent/AR076344A1/es unknown
- 2010-04-20 SG SG2011076940A patent/SG175289A1/en unknown
- 2010-04-20 TW TW099112369A patent/TW201106969A/zh unknown
- 2010-04-20 EP EP10714820A patent/EP2421558A1/en not_active Withdrawn
- 2010-04-20 RU RU2011147051/15A patent/RU2011147051A/ru not_active Application Discontinuation
- 2010-04-20 CA CA2759030A patent/CA2759030A1/en not_active Abandoned
- 2010-04-20 AU AU2010239368A patent/AU2010239368A1/en not_active Abandoned
- 2010-04-20 JP JP2012506004A patent/JP2012524083A/ja active Pending
- 2010-04-20 KR KR1020117027566A patent/KR20120096401A/ko not_active Application Discontinuation
- 2010-04-20 CN CN2010800273827A patent/CN102458467A/zh active Pending
-
2011
- 2011-10-19 CR CR20110553A patent/CR20110553A/es unknown
- 2011-10-19 CL CL2011002610A patent/CL2011002610A1/es unknown
- 2011-10-23 IL IL215764A patent/IL215764A0/en unknown
- 2011-10-24 CO CO11143266A patent/CO6450651A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2011010955A (es) | 2012-04-02 |
JP2012524083A (ja) | 2012-10-11 |
KR20120096401A (ko) | 2012-08-30 |
CN102458467A (zh) | 2012-05-16 |
US20100266589A1 (en) | 2010-10-21 |
WO2010123891A1 (en) | 2010-10-28 |
BRPI1006438A2 (pt) | 2016-09-27 |
RU2011147051A (ru) | 2013-05-27 |
IL215764A0 (en) | 2012-01-31 |
CA2759030A1 (en) | 2010-10-28 |
CR20110553A (es) | 2012-01-23 |
MA33323B1 (fr) | 2012-06-01 |
AU2010239368A1 (en) | 2011-11-10 |
CO6450651A2 (es) | 2012-05-31 |
SG175289A1 (en) | 2011-11-28 |
AR076344A1 (es) | 2011-06-01 |
EP2421558A1 (en) | 2012-02-29 |
TW201106969A (en) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011002610A1 (es) | Metodo de terapia complementaria que comprende la administracion a un paciente con cancer luego de la cirugia definitiva de un antagonista especifico del factor de crecimiento endotelial vascular (vegf) durante mas de un ano; y kit. | |
PH12018500768A1 (en) | Purin derivatives for use in the treatment of fab-related diseases | |
CL2017003218A1 (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
PE20181139A1 (es) | Composiciones y metodos para inhibir la expresion genica de lpa | |
MX344929B (es) | Jeringa con característica de punta desinfectante. | |
ECSP11011327A (es) | Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia | |
PE20191655A1 (es) | Combinaciones farmaceuticas | |
ECSP11011453A (es) | Tratamiento de trastornos cognitivos con determinados receptores de ácido nicotínico alfa-7 en combinación con inhibidores de acetilcolinesterasa | |
EA201290603A1 (ru) | Способ лечения | |
UY33790A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek. | |
CR20130433A (es) | Sistema y mètodo de colocaciòn vascular | |
EA201071209A1 (ru) | Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови | |
CO6531499A2 (es) | Uso de ranolazina para el tratameinto de enfermedades cardiovasculares | |
CY1118925T1 (el) | Θεραπεια ασθενειας με αναστολεις πρωτεασωματος | |
AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
MX2015013409A (es) | Silibina para el tratamiento de alteraciones oxidativas metabolicas en pacientes con esteatohepatitis no alcoholica (nash). | |
DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek | |
CR20120617A (es) | Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
AR081669A1 (es) | Semuloparina para uso como un tratamiento antitrombotico en cirugia ortopedica con perfil beneficio-riesgo mejorado | |
RU2009116087A (ru) | Способ медикаментозного снижения уровня оксидативного стресса у больных артериальной гипертензией | |
UA39741U (uk) | Спосіб проведення дренажу після операції на щитовидній залозі | |
CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek | |
ECSP13012736A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
CO7170027A1 (es) | Composición esporicida y método de utilización de la misma | |
UA43881U (ru) | Способ хирургического лечения облитерирующих поражений артерий нижней конечности |